Meanwhile, research on the mechanism and efficacy of GLP-1R/GIPR dual agonists and GLP-1R/GIPR/GCGR triple agonists paves the way to a ground-breaking therapy specific for obesity, which suggests multi-target drugs may have more advantages than a single target. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.